| Edition |
First edition. |
| Description |
1 online resource. |
| Series |
Cancer sensitizing agents for chemotherapy ; v. 5
|
| Bibliography |
Includes bibliographical references and index. |
| Note |
Online resource; title from PDF title page (EBSCO, viewed March 4, 2019). |
| Contents |
Front Cover; Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy; Copyright; Dedication; Contents; Contributors; About the Editor; About the Series Editor; Aims and Scope for Series ""Cancer Sensitizing Agents for Chemotherapy; Preface; Chapter 1: Overview of Pancreatic Cancer Biology; Introduction; Pathogenesis and Molecular Biology; Three Biological Stages of Cancer Development; Initiation; Clonal Expansion; Oncogenesis; KRAS; Raf/Mitogen-Activated Protein Kinase (MAPK) Cascade; Phosphoinositide 3-Kinase/ATK Cascade; Nuclear Factor Kappa B Signaling Cascade |
|
Tumor Suppressor GenesCDKN2A; TP53; SMAD4; Introduction to Local and Distant Microenvironments; Familial Pancreatic Cancers; Conclusions; References; Further Reading; Chapter 2: Chemoresistance in Pancreatic Cancer: Emphasis on Age and Gender; Introduction; Pancreatic Cancer Incidences and Prognosis: Association of Age and Gender; Chemoresistance: Association With Age and Gender; Mechanisms Associated With Chemoresistance; Factors Modulated in Various Age Groups; Conclusion; Acknowledgments; References; Chapter 3: EMT Contributes to Chemoresistance in Pancreatic Cancer; Introduction |
|
Gemcitabine SensitivityGemcitabine and Chemoresistance; Role of Gemcitabine in Targeting Signaling Pathways; Conclusion; Acknowledgment; References; Chapter 5: Pancreatic Cancer and Possible Therapeutic Options; Introduction; Reasons Behind the Above Statistics?; Brief Outline of Treatment; Tumor-Node-Metastasis Staging and Clinical Classification; Modalities for Evaluating TNM Staging; Clinical Classification; Treatment Options for Pancreatic Adenocarcinoma; Localized Surgically Resectable Stage I and II Disease; Adjuvant Therapy; Gemcitabine and 5-Fluorouracil; Gemcitabine and S-1 |
|
Gemcitabine and CapecitabineAdjuvant Chemoradiation; Gemcitabine Plus Nab-Paclitaxel; Neoadjuvant Therapy; Adjuvant Therapy in Borderline Removable Pancreatic Carcinoma; Evidence Supporting Neoadjuvant Therapy; FOLFIRINOX as Neoadjuvant Therapy; NAC-GSL (Neoadjuvant Chemotherapy-Gemcitabine, S-1, LV); Metastatic Pancreatic Cancer: Treatment Options; Early Period; First-Line Therapies; FOLFIRINOX; PRODIGE-4/ACCORD-11 Trial; Outcomes of PRODIGE-4/ACCORD-11 Trial; Precautionary and Toxicity Reducing Strategies; Gemcitabine Plus Nab-Paclitaxel; The MPACT Trial |
| Subject |
Pancreas -- Cancer.
|
|
Chemotherapy.
|
|
Drug Resistance, Neoplasm. (DNLM)D019008
|
|
Pancreatic Neoplasms -- drug therapy.
(DNLM)D010190Q000188
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Chemotherapy. (OCoLC)fst00853595
|
|
Pancreas -- Cancer.
(OCoLC)fst01051974
|
| Other Form: |
Print version: Nagaraju, Ganji Purnachandra. Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy. First edition. London : Academic Press, [2019] 012817661X 9780128176610 (OCoLC)1078568704 |
| ISBN |
9780128176627 (electronic book) |
|
0128176628 (electronic book) |
|
9780128176610 |
|
012817661X |
|
